Video

Workplace Wellness Can Help Reduce the Risk for Heart Problems

Some Parents May Hasten Death for Terminally Ill Children

Fitness Academics

Secondhand Smoke Increases Risk for Heart Disease in Kids

Toddlers Don't Learn Vocabulary From TV

Despite Worries, Most Parents Vaccinate Their Kids Anyway

Food Allergies Can Be Treated With the Allergen Foods

Signs of Heart Disease Could Be As Early as 3 in Obese Kids

The Number of Women Having Strokes is Rising

Preventative Mastectomy

Cases of Gestational Diabetes Are On the Rise

Nintendo Wii Could Be Therapy for Stroke Victims

Single Men Have An Increased Risk for Stroke

Fatty Foods Could Lead to Stroke in Older Women

Woman Gives Birth After Ovary Transplant

Leukemia Drug May Help Some Ovarian Cancer Patients

Posted on 11/12/2009, 09:00
By -- Randy Dotinga

Sprycel limited the growth of cancer cells in lab study

THURSDAY, Nov. 12 (HealthDay News) -- A drug for people with a form of leukemia holds promise as a possible treatment for ovarian cancer, new research suggests.

The drug dasatinib (Sprycel) is used to treat chronic myeloid leukemia. Researchers at the University of California at Los Angeles report that the drug limited the growth and invasive powers of ovarian cancer cells.

It also proved to have even more cancer-fighting powers when it was combined with chemotherapy and used to fight certain kinds of ovarian cancer cells known as Src dependent, according to the report published in the Nov. 10 issue of the BMJ.

Ovarian cancer is the most deadly cancer that strikes the female reproductive system and is expected to kill 15,500 women in the United States this year. The cancer is very difficult to treat.

"It is important to remember that this work is only on cancer cell lines, but it is significant enough that it should be used to justify clinical trials to confirm that women with this type of ovarian cancer could benefit," Gottfried Konecny, an assistant professor of hematology/oncology and first author of the study, said in a UCLA news release.

An estimated one-third of women with ovarian cancer have the type known as Src dependent.

"We were able to identify markers in the pre-clinical setting that would allow us to predict response to Sprycel," Konecny said. "These may help us in future clinical trials in selecting patients for studies of the drug."

More information

Learn more about ovarian cancer from the U.S. National Cancer Institute.

SOURCE: University of California Los Angeles, news release, Nov. 10, 2009

More news in Leukemia...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.1 / 5 (135 votes)